GlassScriptPhysician profile
Jenna R Daniel
NPI 1821390410
$3,698.02
in general payments reported to CMS, 2019-2025
35 companies · $871 in 2025
The $871 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $572 · 2022: $717 · 2023: $907 · 2024: $632 · 2025: $871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,360 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,360.29 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $982.47 | 2021-2025 | |
| Glaxosmithkline, LLC. | $687.58 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $257.19 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $200.05 | 2024-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $167.46 | 2022-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $165.30 | 2021-2025 | Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $126.52 | 2023-2024 | |
| Pfizer INC. | $110.16 | 2022-2025 | |
| Dexcom, INC. | $102.89 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $87.05 | 2022-2024 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $83.31 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.01 | 2022-2025 | Jardiance |
| Exact Sciences Corporation | $59.13 | 2023-2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $49.22 | 2022-2023 | Rexulti |
| Abbott Laboratories | $45.27 | 2023-2025 | Freestyle Libre 3, Freestyle Libre |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $45.12 | 2025 | Korlym |
| Corium, LLC | $44.74 | 2023 | Azstarys |
| Edwards Lifesciences Corporation | $41.40 | 2025 | Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $40.52 | 2021 | |
| Novo Nordisk INC | $36.10 | 2021-2025 | Wegovy |
| Antares Pharma, INC. | $32.99 | 2022 | |
| Avanir Pharmaceuticals, INC. | $32.22 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.85 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.12 | 2023 | Trintellix |
| Biomerieux INC | $19.74 | 2025 | Biofire Spotfire Control Station |
| Kowa Pharmaceuticals America, INC. | $19.59 | 2022 | |
| Verona Pharma, INC. | $19.53 | 2025 | Ohtuvayre |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.93 | 2025 | Xifaxan |
| Indivior INC. | $17.51 | 2025 | Sublocade |
| Sanofi Pasteur INC. | $17.51 | 2023 | |
| Optos, INC. | $17.35 | 2021 | |
| Amgen INC. | $16.24 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.00 | 2023 | Spravato |
| Radius Health, INC. | $13.21 | 2021 | |
| Genentech USA, INC. | $12.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.